JHL completes assembly of GE built off-the-shelf plant in Wuhan, China

By Gareth Macdonald contact

- Last updated on GMT

Prebuilt modules shipped to China in August (image: GE Healthcare)
Prebuilt modules shipped to China in August (image: GE Healthcare)

Related tags: Monoclonal antibodies

JHL has completed “mechanical construction” of an off-the-shelf mAb plant in Wuhan, China days after UK regulators gave the go ahead for a trial of its rituximab biosimilar, JHL1101.

The new facility was built for JHL by GE Healthcare​ and subcontractor M+W Group in Stuttgart, Germany using GE's modular Kubio technology before being shipped​ to Wuhan for assembly.  

It consists of prebuilt modules containing waste treatment facilities and clean rooms within a 2,400m​floor space. Single-use bioreactors and chromatography equipment was shipped to Wuhan at the end of last year.

The facility will produce JHL’s candidate monoclonal antibodies (mAbs) for late stage trials and commercial supply. It will also be the base of cell line and process development activities and is expected to be validated in June.

UK biosim trial

Completion of the facility comes two weeks after the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granted approval for a Phase I trial of JHL’s most advanced biosimilar candidate, JHL1101,

The trial – which is expected to start this year – is designed to establish JHL1101’s pharmacokinetic and pharmacodynamic similarity to Roche’s MabThera (rituximab), which is known as Rituxan in the US, Canada and Japan.

Supplies of JHL1101 for the Phase I study will be manufactured at JHL’s facility in Hsinchu, Taiwan, which also house processing equipment supplied by GE Healthcare.

If the drug progresses to late Phase trials production is likely to switch to the Wuhan facility, which is also likely to support commercial production should the biosimilar be approved.

JHL also intends to offer use of the Wuhan facility to its contract manufacturing customers and has previously spoken about offering it to the Chinese Government in the event of a pandemic.

Related news

Show more

Related products

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us


View more